JP Morgan Chase
GYRE icon

JP Morgan Chase’s Gyre Therapeutics GYRE Stock Holding History

JP Morgan Chase’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-853
Closed -$26K – 6769
2021
Q3 		$26K Buy
+853
New +$28.1K ﹤0.01% 5992

Other funds holding GYRE

HH
HSG Holding Na, Hong Kong $1.2B AUM 23.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

JP Morgan Chase's GYRE Position: Q2 2026 in Review

JP Morgan Chase increased its Gyre Therapeutics (GYRE) stake by 51% in Q2 2026, buying an estimated $18.1K and bringing the position to 7,831 shares worth $50.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6415.

JP Morgan Chase first reported a position in GYRE in Q2 2013 and has held it in 35 quarters since. The position peaked at $1.85M in Q1 2019. 60 funds tracked by Wall St. Rank hold GYRE as of Q2 2026.

  • JP Morgan Chase held 7,831 shares of Gyre Therapeutics worth $50.5K as of Q2 2026.
  • JP Morgan Chase bought 2,650 Gyre Therapeutics shares in Q2 2026, an estimated $18.1K.
  • Gyre Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6415 holding.
  • JP Morgan Chase first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 35 quarters since.
  • JP Morgan Chase's Gyre Therapeutics position peaked at $1.85M in Q1 2019.
  • 60 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.